Scholar Rock (NASDAQ:SRRK) Insider Akshay Vaishnaw Sells 20,438 Shares

Scholar Rock Holding Corporation (NASDAQ:SRRK) insider Akshay Vaishnaw sold 20,438 shares of the firm’s stock in a transaction that occurred on Tuesday, January 13th. The stock was sold at an average price of $42.70, for a total transaction of $872,702.60. Following the sale, the insider owned 595,767 shares of the company’s stock, valued at approximately $25,439,250.90. This represents a 3.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.

Scholar Rock Stock Up 2.1%

SRRK stock opened at $46.53 on Friday. The company has a 50 day moving average of $42.02 and a two-hundred day moving average of $36.87. The company has a market cap of $4.75 billion, a price-to-earnings ratio of -14.77 and a beta of 0.63. Scholar Rock Holding Corporation has a 12-month low of $22.71 and a 12-month high of $48.28. The company has a quick ratio of 6.30, a current ratio of 6.30 and a debt-to-equity ratio of 0.41.

Scholar Rock (NASDAQ:SRRK) last posted its quarterly earnings results on Friday, November 14th. The company reported ($0.90) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.88) by ($0.02). During the same period last year, the business earned ($0.66) EPS. On average, equities analysts anticipate that Scholar Rock Holding Corporation will post -2.42 earnings per share for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on SRRK. UBS Group started coverage on Scholar Rock in a report on Wednesday, January 7th. They set a “buy” rating and a $60.00 price target for the company. Piper Sandler cut their price objective on shares of Scholar Rock from $52.00 to $51.00 and set an “overweight” rating on the stock in a research report on Wednesday, September 24th. Bank of America started coverage on shares of Scholar Rock in a research note on Thursday, October 9th. They issued a “buy” rating and a $53.00 target price for the company. Cantor Fitzgerald restated an “overweight” rating on shares of Scholar Rock in a research note on Thursday, December 11th. Finally, Citigroup began coverage on shares of Scholar Rock in a report on Friday, January 9th. They set a “buy” rating and a $55.00 price target on the stock. Four investment analysts have rated the stock with a Strong Buy rating, thirteen have issued a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Buy” and an average price target of $50.14.

Hedge Funds Weigh In On Scholar Rock

A number of institutional investors have recently modified their holdings of SRRK. Wellington Management Group LLP boosted its holdings in shares of Scholar Rock by 124.5% during the 3rd quarter. Wellington Management Group LLP now owns 4,545,887 shares of the company’s stock worth $169,289,000 after buying an additional 2,521,022 shares during the period. Holocene Advisors LP acquired a new position in Scholar Rock during the 3rd quarter worth $91,670,000. Norges Bank bought a new stake in Scholar Rock during the second quarter valued at about $41,628,000. Balyasny Asset Management L.P. acquired a new stake in shares of Scholar Rock in the second quarter valued at about $33,062,000. Finally, UBS Group AG grew its position in shares of Scholar Rock by 233.8% in the third quarter. UBS Group AG now owns 1,131,787 shares of the company’s stock valued at $42,148,000 after purchasing an additional 792,760 shares during the last quarter. Institutional investors own 91.08% of the company’s stock.

About Scholar Rock

Scholar Rock is a clinical-stage biotechnology company focused on the discovery and development of protein therapeutics that selectively target growth factors involved in disease processes. The company’s research platform is designed to modulate endogenous growth factor activation and signaling with high specificity, aiming to restore normal biological function across a range of disorders. Scholar Rock’s approach is distinguished by its emphasis on engineering antibodies and biologics that interact with growth factor precursors or latent complexes rather than the active form, potentially offering improved safety and efficacy profiles.

The company’s lead program, SRK-015 (appercept), is an investigational monoclonal antibody targeting the activation of latent myostatin proproteins and is being evaluated for the treatment of spinal muscular atrophy (SMA).